<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HAF6C444EEBFE47E1A3A12C8A60B2C592" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 3884 IH: Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-06-07</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 3884</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230607">June 7, 2023</action-date><action-desc><sponsor name-id="B001248">Mr. Burgess</sponsor> (for himself, <cosponsor name-id="D000096">Mr. Davis of Illinois</cosponsor>, and <cosponsor name-id="C001103">Mr. Carter of Georgia</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XI of the Public Health Service Act to reauthorize the program providing for sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment.</official-title></form><legis-body id="H1ECBD73CE4904A64A7AF6F395A75DADB" style="OLC"> 
<section id="H75BDF4BAFEE940DD8B4C7476B1A7DAE0" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023</short-title></quote>.</text></section> <section id="H01EA0C4AFE04476A83BD02569A762AA8"><enum>2.</enum><header>Reauthorization of sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment</header><text display-inline="no-display-inline">Section 1106(b)(6) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300b-5">42 U.S.C. 300bâ€“5(b)(6)</external-xref>) is amended by striking <quote>2019 through 2023</quote> and inserting <quote>2024 through 2028</quote>. </text> </section> 
</legis-body></bill>

